<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47720">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484963</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Insomnia-001</org_study_id>
    <nct_id>NCT02484963</nct_id>
  </id_info>
  <brief_title>The Study of Spectrum of Sleep Disorders in Cirrhotic Patients and the Efficacy of Zolpidem in Cirrhotic Patients With Insomnia</brief_title>
  <official_title>The Study of Spectrum of Sleep Disorders in Cirrhotic Patients and the Efficacy of Zolpidem in Cirrhotic Patients With Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All Cirrhosis liver patients (Child A/B/C) presenting to Institute of Liver and Biliary
      Sciences will be screened for sleep disturbance and excessive daytime sleepiness with
      Epworth sleep score/ Pittsburgh sleep quality index. 50 patients of clinical/ radiological/
      biopsy proven cirrhosis (Child A/B) will be enrolled after ruling out possibility of
      psychiatric illnesses like depression and anxiety with the help of PHQ-9 / GAD-7
      questionnares. Patients who are suffering with sleep disturbance as evaluated with
      Pittsburgh sleep quality index will undergo polysomnography and will be randomised to two
      groups after fulfilling all inclusion criterias. Patients in group (Group 1) will receive
      zolpidem 5mg at bed time daily and patients in control group will receive placebo at bed
      time daily. The treatment will be continued for 4 weeks. After 4 weeks enrolled patients
      will be reassessed with PSQI and polysomnography. All patients will be advised regarding
      sleep hygiene.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in quality of sleep in CHILD A/B cirrhosis patients after 4 weeks as measured by PSQI score ( ≥ 40% improvement in score )</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Precipitation of Hepatic encephalopathy with Zolpidem</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in daytime sleepiness with zolpidem as measured by ESS</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in sleep efficiency after treatment</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in periodic limb movements after treatment</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>zolpidem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet zolpidem 5mg once daily will be given for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet of placebo will be given for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <arm_group_label>zolpidem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 70 years

          -  Clinical, Biochemical, Radiological ,Histological evidence of cirrhosis of all
             etiology

          -  Child A and B cirrhosis (for intervention part)

          -  Cirrhosis patients giving h/o persistent sleep disturbances (PSQI≥5)

          -  Child A, B and C cirrhosis (for observational part)

        Exclusion Criteria:

          -  Active alcohol intake or intake within 1 month of enrollment

          -  Active substance abuse or intake within 1 month of enrollment

          -  Known psychiatric and neurological disorders

          -  Patient using antidepressant, anticonvulsants, other hypnotics

          -  Pregnancy or lactation

          -  Overt hepatic encephalopathy (grade 2,3,4)

          -  Child C cirrhosis (for intervention part)

          -  Acute decompensated state of CLD (Chronic Liver Disease) - GastroIntestinal bleed,
             increased jaundice, HE (Hepatic Encepahlopahty) , SBP (Spontaneous Bacterial
             Peritonitis).

          -  HCC (HepatoCellular Carcinoma) with portal vein thrombosis

          -  Acute febrile illness/ acute infection

          -  Post TIPS (Transjugular Intrahepatic Portosystemic shunt)patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sumeet Kainth, MD</last_name>
    <phone>+91-11-46300000</phone>
    <email>sumeetkainth@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>August 20, 2016</lastchanged_date>
  <firstreceived_date>May 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
